^
Association details:
| Biomarker: | HER-2 expression + HER-2 amplification |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.
Published date:
01/11/2021
Excerpt:
First-line triplet regimen (Pembrolizumab, Trastuzumab, and Chemotherapy) showed promising efficacy based on HER2 amplification by NGS regardless of PD-L1 status in AGC/GEJ cancer.
Secondary therapy:
cisplatin + capecitabine
DOI:
10.1200/JCO.2021.39.3_suppl.218
Trial ID:
